login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SOLIGENIX INC (SNGX) Stock News
USA
-
Nasdaq
- NASDAQ:SNGX -
US8342236044
-
Common Stock
1.58
USD
-0.07 (-4.24%)
Last: 12/15/2025, 12:33:27 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SNGX Latest News, Press Relases and Analysis
All
Press Releases
10 days ago - By: Soligenix, Inc.
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
10 days ago - By: Soligenix, Inc.
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
12 days ago - By: Soligenix, Inc.
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
12 days ago - By: Soligenix, Inc.
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
11 days ago - By: BioMedWire
- Mentions:
AMGN
FOLD
CTOR
TNXP
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
a month ago - By: Soligenix, Inc.
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
2 months ago - By: Stocktwits
Soligenix Logs Best Session In Nearly 2 Months After Safety Win In T-Cell Lymphoma Trial — Traders Eye Multiday Rally
13 days ago - By: BioMedWire
- Mentions:
PFE
MRK
BMY
INSM
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
a month ago - By: Soligenix, Inc.
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
2 months ago - By: Soligenix
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
2 months ago - By: Soligenix, Inc.
Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
3 months ago - By: Soligenix, Inc.
Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
3 months ago - By: Soligenix, Inc.
Soligenix Announces Closing of $7.5 Million Public Offering
3 months ago - By: Benzinga
- Mentions:
CASI
SSKN
CRNX
APLT
...
12 Health Care Stocks Moving In Friday's Intraday Session
3 months ago - By: Benzinga
- Mentions:
DRIO
CLSD
CRNX
ORGO
...
12 Health Care Stocks Moving In Friday's Pre-Market Session
3 months ago - By: Soligenix, Inc.
Soligenix Announces Pricing of $7.5 Million Public Offering
3 months ago - By: Soligenix, Inc.
Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor
3 months ago - By: Soligenix, Inc.
Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses
3 months ago - By: Soligenix, Inc.
Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Please enable JavaScript to continue using this application.